Lana Zhovtis Ryerson

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing

Lana Zhovtis Ryerson, John Foley, Ih Chang et al. · Neurology · 2019 · 186 citations · Full text

COVID-19 outcomes in MS

Erica Parrotta, Ilya Kister, Leigh Charvet et al. · Neurology Neuroimmunology & Neuroinflammation · 2020 · 148 citations · Full text

Extended interval dosing of natalizumab in multiple sclerosis

Lana Zhovtis Ryerson, Teresa C. Frohman, John Foley et al. · Journal of Neurology Neurosurgery & Psychiatry · 2016 · 146 citations

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

John Foley, Gilles Defer, Lana Zhovtis Ryerson et al. · The Lancet Neurology · 2022 · 103 citations

Relapsing-remitting Multiple Sclerosis, Clinical Neurology, Clinical Trials +8

Association of Disease Severity and Socioeconomic Status in Black and White Americans With Multiple Sclerosis

Karla Gray-Roncal, Kathryn C. Fitzgerald, Lana Zhovtis Ryerson et al. · Neurology · 2021 · 59 citations · Full text